The #1 prescribed novel oral
anticoagulant in the US*1
The patients they studied are the ones I see.
AMONG NOVEL ORAL ANTICOAGULANTS:
Most real-world experience: more than 2 million patients prescribed
in the US.2
Most safety data generated in clinical trials in patients
studied with high risk of thrombotic events.†3-16
Most affordable: the lowest average
out-of-pocket cost.17
Not intended to be a comparison of safety
or efficacy outcomes.
*Among Factor Xa inhibitors and direct thrombin inhibitors.
†
Based on the following: CHADS2 scores 3-6 in ROCKET AF (N=12,402), ARISTOTLE
(N=5502), ENGAGE-AF (N=~11,200), and RE-LY (N=5882); risk factors of DVT, PE,
DVT/PE, cancer, elderly, previous VTE, provoked VTE, unprovoked VTE, and recent
trauma or surgery in EINSTEIN pooled analysis (N=8281), AMPLIFY (N=5395),
Hokusai-VTE (N=8240), and RE-COVER I and II (N=5107).
IMPORTANT SAFETY INFORMATION
WARNING: (A) PREMATURE DISCONTINUATION OF
XARELTO® INCREASES THE RISK OF THROMBOTIC
EVENTS, (B) SPINAL/EPIDURAL HEMATOMA
A. PREMATURE DISCONTINUATION OF XARELTO®
INCREASES THE RISK OF THROMBOTIC EVENTS
Premature discontinuation of any oral anticoagulant,
including XARELTO®, increases the risk of thrombotic
events. If anticoagulation with XARELTO® is
discontinued for a reason other than pathological
bleeding or completion of a course of therapy,
consider coverage with another anticoagulant.
B. SPINAL/EPIDURAL HEMATOMA
Epidural or spinal hematomas have occurred in
patients treated with XARELTO® who are receiving
neuraxial anesthesia or undergoing spinal puncture.
These hematomas may result in long-term or
permanen Ё